Education
About Us
Working with TipRanks
Follow Us
Biofrontera, Inc. (DE:AI10)
:AI10
Total Valuation
Biofrontera has a market cap or net worth of €5.49M. The enterprise value is ―.
Market Cap€5.49M
Enterprise Value―
Share Statistics
Biofrontera has 9,446,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,446,197
Owned by Insiders20.14%
Owned by Institutions7.75%
Financial Efficiency
Biofrontera’s return on equity (ROE) is -4.01 and return on invested capital (ROIC) is -162.13%.
Return on Equity (ROE)-4.01
Return on Assets (ROA)-0.80
Return on Invested Capital (ROIC)-162.13%
Return on Capital Employed (ROCE)-1.71
Revenue Per Employee405.47K
Profits Per Employee-193.03K
Employee Count92
Asset Turnover1.69
Inventory Turnover2.69
Valuation Ratios
The current PE Ratio of Biofrontera is -338.58. Biofrontera’s PEG ratio is -4.32.
PE Ratio-338.58
PS Ratio0.00
PB Ratio1.01K
Price to Fair Value1.36K
Price to FCF-0.70
Price to Operating Cash Flow-436.69
PEG Ratio-4.32
Income Statement
In the last 12 months, Biofrontera had revenue of 37.30M and earned -17.76M in profits. Earnings per share was 0.00.
Revenue37.30M
Gross Profit19.45M
Operating Income-17.21M
Pretax Income-17.74M
Net Income-17.76M
EBITDA-14.48M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -10.27M and capital expenditures -10.00K, giving a free cash flow of -10.28M billion.
Operating Cash Flow-10.27M
Free Cash Flow-10.28M
Free Cash Flow per Share-1.09
Dividends & Yields
Biofrontera pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.58
52-Week Price Change-22.06%
50-Day Moving Average0.80
200-Day Moving Average0.86
Relative Strength Index (RSI)37.25
Average Volume (3m)0.00
Important Dates
Biofrontera upcoming earnings date is Sep 30, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateSep 30, 2025
Ex-Dividend Date―
Financial Position
Biofrontera as a current ratio of 1.72, with Debt / Equity ratio of 111.03%
Current Ratio1.72
Quick Ratio1.17
Debt to Market Cap<0.01
Net Debt to EBITDA0.07
Interest Coverage Ratio-8.17
Taxes
In the past 12 months, Biofrontera has paid 22.00K in taxes.
Income Tax22.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Biofrontera EV to EBITDA ratio is -415.12, with an EV/FCF ratio of -584.81.
EV to Sales161.16
EV to EBITDA-415.12
EV to Free Cash Flow-584.81
EV to Operating Cash Flow-585.38
Balance Sheet
Biofrontera has €5.91M in cash and marketable securities with $4.92M in debt, giving a net cash position of -€990.00K billion.
Cash & Marketable Securities€5.91M
Total Debt$4.92M
Net Cash-€990.00K
Net Cash Per Share-€0.10
Tangible Book Value Per Share<€0.01
Margins
Gross margin is 52.14%, with operating margin of -46.14%, and net profit margin of -47.61%.
Gross Margin52.14%
Operating Margin-46.14%
Pretax Margin-47.55%
Net Profit Margin-47.61%
EBITDA Margin-38.82%
EBIT Margin-41.90%
Analyst Forecast
The average price target for Biofrontera is €6.26, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€6.26
Price Target Upside682.85% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―